Study of Intravenous Aflibercept in Combination With FOLFIRI in Japanese Patients With Metastatic Colorectal Cancer
The primary objective is to determine the dose of aflibercept to be further studied in combination with irinotecan/5-fluorouracil/isovorin (FOLFIRI) in Japanese patients with metastatic colorectal cancer.

Secondary objectives of this study are to assess the safety profile of aflibercept, to determine the pharmacokinetics of aflibercept, to make a preliminary assessment of antitumor effects.
Colorectal Neoplasms|Neoplasm Metastasis
DRUG: AVE0005 (aflibercept)
Dose-limiting toxicity (DLT) combination with FOLFIRI, During the first 2 cycles (4 weeks) of study treatment
physical examination, laboratory safety tests, adverse events, up to 60 days after last treatment|Pharmacokinetics, up to 90 days after last treatment|Tumor burden, endogenous free VEGF, every 3 cycles|Immunogenicity, up to 90 days after last treatment
The primary objective is to determine the dose of aflibercept to be further studied in combination with irinotecan/5-fluorouracil/isovorin (FOLFIRI) in Japanese patients with metastatic colorectal cancer.

Secondary objectives of this study are to assess the safety profile of aflibercept, to determine the pharmacokinetics of aflibercept, to make a preliminary assessment of antitumor effects.